• Japanese
  • Korean
  • Chinese
Cover Image

Anticoagulants

Product Description

This report analyzes the worldwide markets for Anticoagulants in Millions of US$ by the following Product Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecastsare provided for the period of 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 45 companies including many key and niche players such as Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi, Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions And Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • A Prelude
  • Anticoagulants- An Evolving Market
  • Injectables or Oral Drugs - The Road Ahead
  • Conventional Oral Drugs to Face the Heat Too
  • New Drugs yet to Gain Mainstream Status
  • Sizing the Market

2. INDUSTRY OVERVIEW

  • Issues with Traditional Drugs Fueling the Hunt for New Anticoagulants
  • New Therapies: Need of the Hour
  • Drug Advancements Drive Anticoagulant Market
  • Niche Markets - The New Target for Drug Makers
  • Anticoagulant Therapy in IPF: Reduces Mortality Risk
  • Anticoagulants to Lose UA/AMI Markets to Antiplatelets
  • An Opportunity to Grow Further
  • Warfarin & Heparins: The Former Market Leaders
  • Generics Drugs Prevail in the Anticoagulant Market
  • Concern Over Underutilization of Warfarin
  • Novel Oral Anticoagulants to Turbo-Charge Market Growth
  • Hurdles Exist for New Oral Agents
  • The Merits and Demerits of New Age Anticoagulants
  • Lack of Adequate Trials Mar Pediatric Anticoagulants Market
  • Improved Anticoagulant Agents for Children Group
  • Growing Demand for Self-Testing
  • LMWHs Ease Outpatient Management
  • Novel Heparins Enhance Market Potential
  • A Focus on Failed or Withdrawn Agents in Recent Past
  • Idraparinux and Idrabiotaparinux Sodium - Sanofi's Discontinued Agents
  • Lack of Statistical Significance Leads to Culmination of Tecarfarin's Development
  • Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma

3. ORAL ANTICOAGULANT AGENTS

  • Traditional Oral Anticoagulants
  • Warfarin
    • Advantages and Alternatives
    • Side Effects
    • Limitations
  • Coumadin - The Branded Warfarin
  • Novel Oral Anticoagulants
  • Dabigatran Etexilate (Pradaxa)
    • Table 1: Pradaxa and Warfarin - A Comparative Study
    • Approved Indications for Pradaxa in Select Regions
  • Rivaroxaban (Xarelto)
    • Approved Indications for Xarelto in Select Regions
    • Xarelto Patent Expiration in Various Regions
  • Apixaban (Eliquis)
  • Betrixaban
  • Comparison of Select Approved and Pipeline Anticoagulant Agents in a Nutshell
  • Market Dynamics
  • New Oral Drugs More Efficacious In Reducing Stroke
  • New Generation Anticoagulants Enter the Market, Warfarin Comes Under Pressure
  • Oral Anticoagulants Market to Witness Intense Competition
  • Pradaxa- A High Potential Replacement to Warfarin
  • Packaging May Hurt Pradaxa's Prospects
  • New Oral Drugs in Various Indications
  • Emerging Targets in the Anticoagulation Space
  • Daiichi Sankyo Upbeat on Prospects of Edoxaban
  • ELIQUIS' FDA Approval Faces Further Delays
    • The ARISTOTLE Trial
  • Eliquis - More Promising than Existing Oral Anticoagulants
  • Competitors Capitalize on Delay in Eliquis' Approval
  • Do New Oral Anticoagulants Circumvent Issues with Conventional Drugs?
  • Hemostatic Agents for Reversing Action of New Oral Drugs - An Area Demanding Active Research

4. INJECTABLE ANTICOAGULANTS

  • Injectable Anticoagulants- An Insight
  • Heparin - The Back Bone of Injectable Anticoagulants
  • Unfractionated Heparin
    • Advantages and Alternatives
    • Limitations
  • Low Molecular Weight Heparins
    • Indications
    • Advantages
    • Contraindications
    • Side Effects
    • Caution
    • Costs
    • Impediments
  • A Focus on Select Heparin Based Injectables
  • Lovenox/Clexane (enoxaparin)
    • Approved Indications for Lovenox
    • Advantages and Alternatives
    • Table 2: World Lovenox Sales by Geographic Region (2009-2011): Breakdown of Value Sales in US$ Million for Western Europe, US, Emerging Markets and Others (includes corresponding Graph/Chart)
  • Fragmin (dalteparin sodium)
    • Approved Indications for Fragmin Use
    • Contraindications
    • Precautions
  • Fraxiparine (nadroparin)
  • Innohep (tinzaparin)
    • Contraindications
    • Side Effects
    • Other Serious Adverse Events Associated with Innohep
    • Precautions
  • Normiflo (ardeparin)
  • Clivarine (reviparin)
    • Table 3: Summary of Available LMWHs
  • A Comparison of FDA Approved Indications for Select Injectable LMWHs - Lovenox, Innohep and Fragmin
  • Non-Heparin Anticoagulant Injectables - An Overview
  • Arixtra (fondaparinux)
    • Contraindications
    • Market and Market Participants
  • Angiomax (bivalirudin)
    • Advantages
    • Contraindications
    • Side Effects
  • Argatroban/Novastan
    • Side Effects
    • Precautions
  • Refludan (lepirudin)
  • Orgaran (danaparoid Sodium)
    • Contraindications
    • Side Effects
    • Caution
    • Precaution
  • A Comparative Analysis of Various Direct Thrombin Inhibitors

5. A COMPARATIVE STUDY OF ANTICOAGULANT THERAPIES

  • A Comparative Study of Warfarin Against LMWHs
  • A Comparative Study of LMWH Against UFH
  • A Comparative Study of New Anticoagulants/ Anticoagulant Candidates Against Warfarin
  • A Comparative Study of Heparin Against Angiomax
  • A Comparative Study of Arixtra Against UFH and LMWH
  • A Comparative Study of Angiomax Against UFH and LMWH

6. AREAS OF INDICATION

  • Indications for Anticoagulant Use
  • Venous/DVT Thrombosis Indications
    • Desired Anticoagulant Qualities for DVT Indications
    • Venous Thromboembolism
      • Deep Vein Thrombosis
      • Pulmonary Embolism
    • Orthopedic (Hip or Knee Replacement) Surgery
    • General Surgery
    • Cancer
  • Arterial Thrombosis Indications
    • Arterial Thrombosis
      • Acute Coronary Syndromes
      • Atrial Fibrillation
      • Unstable Angina
      • List of Approved Anticoagulants for Unstable Angina
      • Myocardial Infraction
      • Non ST-Segment Elevation MI
      • List of Approved Anticoagulants for Non-ST Segment Elevation Myocardial Infarction
      • Percutaneous Transluminal Coronary Angioplasty (PTCA)
      • List of Approved Anticoagulants for Angioplasty Procedures
  • Heparin Induced Thrombocytopenia (HIT) Indications
    • HIT Type I
    • HIT Type II
    • Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
  • Other Indications
    • Hemodialysis

7. DRUG DEVELOPMENT PIPELINE

  • Select Anticoagulants in Clinical Development
  • Anticoagulant Therapies in Development Stage
  • Idraparinux - Sanofi
  • 0673 - Sanofi
  • MER-102
  • Semuloparin Sodium (AVE 5026)

8. PRODUCT INTRODUCTIONS/APPROVALS

  • Mitsubishi Pharma Introduces Argatroban in the UK
  • Bayer Obtains Canadian Approval for Xarelto in the Treatment of Deep Vein Thrombosis
  • Pradaxa Gains Regulatory Approval in Japan for Prevention of Stroke
  • Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug
  • ELIQUIS(r) Receives Approval in EU in Prevention of VTE
  • Xarelto Obtains Approval in UK
  • Xarelto Receives FDA Approval for Prevention of DVT
  • Eisai Launches Warfarin Granules 0.2% in Japan
  • Amphastar Receives FDA Approval for ANDA of Enoxaparin Sodium Injection
  • Boehringer Ingelheim Obtains EU Approval for Pradaxa in AF
  • Daiichi Sankyo Introduces Edoxaban Tablets in Japan

9. PRODUCT INTRODUCTIONS/APPROVALS IN RECENT PAST- A PERSPECTIVE BUILDER

  • GSK Receives EU Approval for Arixtra(r)
  • Pradaxa Receives FDA Approval
  • Canyon Pharmaceuticals Introduces Iprivask
  • Teva Receives FDA's Tentative Approval for Argatroban
  • TrimGen Receives FDA 510(k) Approval for Marketing eQ- PCR(tm) LC Warfarin Genotyping Kit
  • Lundbeck Launches ATryn(r) Commercially in the US
  • The Medicines Co Receives European Approval for Angiox (Bivalirudin)

10. RECENT INDUSTRY ACTIVITY

  • FDA Issues Complete Response Letter for Eliquis's New Drug Application
  • FDA Issues Complete Response Letter to Rivaroxaban's (Xarelto) NDA for ACS
  • US FDA Extends Date for Eliquis' New Drug Application
  • Pradaxa(r) Receives NICE Recommendation
  • BioInvent and ThromboGenics Discontinue Development of TB-402
  • Watson Receives Stay Order on Preliminary Injunction
  • FDA Assigns Priority Review for Xarelto Supplemental NDA
  • Portola Pharmaceuticals Re-Acquires Rights to Betrixaban
  • FDA Accepts New Drug Application for ELIQUIS(r)
  • Astellas Pharma Halts Development of Anticoagulant
  • Sanofi-Aventis Changes Name to Sanofi

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER

  • Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim
  • Sagent Pharmaceuticals Secures FDA Approval for Heparin Sodium Injection
  • Biomet Acquires Cytosol Laboratories
  • Portola Inks $470 M Agreement with Merck for Phase II Anticoagulant
  • Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma
  • Nuvelo and ARCA biopharma Merge

12. FOCUS ON SELECT GLOBAL PLAYERS

  • Bayer Healthcare AG (Germany)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Eisai Inc. (USA)
  • GlaxoSmithKline plc (UK)
  • LEO Pharmaceutical Products (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Pfizer Inc. (USA)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Teva Pharmaceuticals USA (USA)

13. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 5: World Historic Review for Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 6: World 15-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 7: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 8: World Historic Review for Oral Anticoagulants by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 9: World 15-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 10: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Injectable Anticoagulants by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Unfractionated Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 18: World 15-Year Perspective for Unfractionated Heparin by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Atrial Fibrillation - A Key Risk Factor
    • Price Controls
    • US Anticoagulants Market
      • FDA Approved Anticoagulants
    • Table 22: Novel Drugs/Drug Candidates in the US Anticoagulants Market
    • Table 23: US Vitamin K Antagonists Market (2011): Percentage Breakdown of Value Sales by Drug- Coumadin, Warfarin Generics and Others (includes corresponding Graph/Chart)
    • Table 24: US Direct Thrombin (II) Inhibitors Market (2011): Percentage Breakdown of Value Sales by Drug - Pradaxa, Angiomax, Argatroban, Refludan and Others (includes corresponding Graph/Chart)
    • Table 25: US Market for Xarelto (2011): Percentage Share Breakdown of Sales by Indication- Atrial Fibrillation and DVT Prevention in Surgery (includes corresponding Graph/Chart)
      • Payers Keen on New Therapies
      • Pradaxa's Initial Performance Commendable, Conventional AVK Products Still Dominate
      • US Heparin Market
      • Hinging on Market Opportunities
      • Generics - Threatening Branded Anticoagulants
    • List of Patent Protected Anticoagulants in the US
    • Generic Competition Threatens Sanofi's Lovenox
    • Table 26: Leading Players in the US Enoxaparin Sodium Market (2011): Percentage Breakdown of Sales for Sandoz and Sanofi (includes corresponding Graph/Chart)
    • Table 27: US Enoxaparin Sodium Market by Sector (2011): Percentage Breakdown of Sales for Institutional and Retail Sectors (includes corresponding Graph/Chart)
    • Ignorance - A Major Hindrance
    • Future Challenges and Growth Drivers
    • US Emerging Anticoagulant Market
    • Product Introductions/Approvals
    • Recent Industry Activity
    • Focus on Select Players
  • B. Market Analytics
    • Table 28: US Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 29: US Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 30: US 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Outlook
    • Anticoagulants Market in Japan
    • Rising Incidence of Pulmonary Thromboembolism
    • Product Introductions/Approvals
    • Recent Industry Activity
    • Focus on Select Players
      • Regional Player
  • B. Market Analytics
    • Table 31: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 32: Japanese Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 33: Japanese 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Outlook
    • Market in High Need of an Ideal Therapy
    • Product Introductions/Approvals
  • B. Market Analytics
    • Table 34: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 35: European Historic Review for Anticoagulants by Geographic Region / Country - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 36: European 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 37: European Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 38: European Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 39: European 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3a. FRANCE

  • A. Market Analysis
    • Outlook
    • Recent Industry Activity
    • Focus on Select Players
  • B. Market Analytics
    • Table 40: French Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 41: French Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 42: French 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3b. GERMANY

  • A. Market Analysis
    • Outlook
    • Market Drivers for Injectable Anticoagulants
    • Anticoagulants Growth Drive European POC Testing Market
    • Focus on Select Players
  • B. Market Analytics
    • Table 43: German Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 44: German Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 45: German 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3c. ITALY

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 46: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 47: Italian Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 48: Italian 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Product Introductions/Approvals
    • Recent Industry Activity
    • Focus on Select Players
  • B. Market Analytics
    • Table 49: UK Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 50: UK Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 51: UK 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3e. SPAIN

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 52: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 53: Spanish Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 54: Spanish 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

3f. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Focus on Select Player
  • B. Market Analytics
    • Table 55: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 56: Rest of Europe Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 57: Rest of Europe 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Heparin Market in China Gains Momentum
    • Product Introduction/Approval
    • Focus on Select Player
  • B. Market Analytics
    • Table 58: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 59: Rest of World Historic Review for Anticoagulants by Product Segment - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 60: Rest of World 15-Year Perspective for Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Show More
Pricing